Companies: 10,795·Total market cap: $144.5T
ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQRNASDAQHealthcare● Active
$1.53
+$0.03(+2.00%)
Market Cap$161202330
P/E Ratio
52W High$3.1
52W Low$1.33
Overview

ProQR Therapeutics N.V. (PRQR) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

prqr · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 10 Wall Street analysts in the past 3 months

SellBuy

Buy

10 analysts

consensus

Rating Breakdown

Strong Buy
1
Buy
8
Hold
1
Sell
0
Strong Sell
0
Total: 10 · Buy rate: 90.0%

12-Month Price Target

High

$5.00

Consensus

$3.63

+137.3% upside

Low

$2.00

Median: $3.75 · Last Close: $1.53

The ProQR Therapeutics N.V. (PRQR) analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month PRQR price target is $3.63, representing +137.3% upside from the current price of $1.53.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $4 (137.3%)

Consensus Target

$3.63

137.3% upside

High Target

$5

226.8%

Low Target

$2

30.7%

Current Price

$1.53

as of today

Based on analyst price targets, the PRQR stock price prediction for the next 12 months ranges from $2 to $5. The consensus PRQR price forecast of $3.63 implies 137.3% upside from the current price of $1.53.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$1.501.66%

1-day model range: $1.49–$1.52. Peak: $1.52 (-1.66%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$1-50.0%
2028$1-62.5%
2029$1-67.2%
2030$0-69.2%
2031-70.2%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

29%7%64%
4Buy
1Neutral
9Sell
RSI (14)51.7Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PRQR · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$1.50BUY
MA 10$1.52BUY
MA 20$1.54SELL
MA 50$1.64SELL
MA 100$1.62SELL
MA 200$1.94SELL
Current $PRQR · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$1.51BUY
EMA 10$1.51BUY
EMA 20$1.54SELL
EMA 50$1.60SELL
EMA 100$1.69SELL
EMA 200$1.85SELL
Current $PRQR · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Chardan Capital2026-04-09
Maintains
BuyBuy
Chardan Capital2025-11-04
Maintains
BuyBuy
Chardan Capital2025-08-08
Maintains
BuyBuy
JMP Securities2025-06-27
Maintains
Market OutperformMarket Outperform
Cantor Fitzgerald2025-06-27
Maintains
OverweightOverweight
Oppenheimer2025-05-13
Maintains
OutperformOutperform
Chardan Capital2025-03-14
Maintains
BuyBuy
HC Wainwright & Co.2025-03-14
Maintains
BuyBuy
JMP Securities2024-12-12
Maintains
Market OutperformMarket Outperform
HC Wainwright & Co.2024-12-12
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on ProQR Therapeutics N.V. (PRQR) stock. Of the recent 47 rating actions, 4 were upgrades and 2 were downgrades. 10 analysts currently cover PRQR.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

PRQR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$21M

↓ 64.8% YoY

Revenue Next Year

$17M

↓ 18.6% YoY

EPS This Year

$-0.52

EPS Next Year

$-0.60

↑ 15.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PRQR EPS of $-0.52 for the current fiscal year, based on estimates from 4 analysts. The PRQR revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PRQR stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRQR price target is $3.63 (+137.3% upside), with an analyst consensus of Buy.

The PRQR short-term stock prediction for tomorrow is $1.50 (-1.66%). The PRQR stock price prediction for 2027 estimates an average of $1. The PRQR stock prediction for 2030 projects a range of $0–$1.

ProQR Therapeutics N.V. trades on NASDAQ under the ticker PRQR. The PRQR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 90% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PRQR forecast · 8 questions

According to 10 Wall Street analysts, the average 12-month PRQR price target is $3.63, with a high forecast of $5.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +137.3% potential upside from the current price of $1.53.

PRQR price targetWhat is PRQR price targetPRQR analyst price targetPRQR 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.